Knowledge management platform for clinical use of brain data

Información del proyecto

BrainBase

Identificador del acuerdo de subvención: 826898

DOI

10.3030/826898

Proyecto cerrado

Fecha de la firma de la CE 2 Agosto 2018

Fecha de inicio 1 Septiembre 2018

Fecha de finalización 28 Febrero 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

BIOMAX INFORMATICS AG
Germany

Periodic Reporting for period 1 - BrainBase (Knowledge management platform for clinical use of brain data)

Período documentado: 2018-09-01 hasta 2019-02-28

Resumen del contexto y de los objetivos generales del proyecto

The connectome is a map of all neural connections in the brain that can provide information about the brain’s (re)wiring in neurological diseases, injuries, or drugs responses. The use of connectomes in clinical practice has enormous potential to improve treatment efficacy, enhance patient stratification, disease characterization, and ultimately diagnosis. However, the means to clinically utilize connectomes are limited. Therefore neurologists still rely on subjective analysis of brain scans. Although the use of big data tools in neuro-diagnostics is growing, no commercial application for clinical practice is available yet.

Biomax developed the first commercial solution to translate big connectome data into clinically relevant information: NeuroXM. In combination with patients’ clinical data this can be valorized to improve neuro-diagnosis. NeuroXM has successfully undergone pilot studies at two major institutes. The proprietary NeuroXM platform includes all features and security levels that are required in the clinic. Biomax is a strong bioinformatic SME with 20 years’ experience, including >25 European grants, 5 successful bioinformatic products, and a pioneering reputation.

The objective of the current project was to assess the feasibility of different potential clinical applications of NeuroXM, which will help Biomax to establish a Go/No-go for further clinical validation for the specific clinical applications

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

This feasibility study has assessed different clinical applications, target markets, and a go-to market strategies.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The feasibility study led to the identification of several feasible clinical applications for NeuroXM as well as accessible target markets, generating a go-to market strategy which will help Biomax to proceed to further clinical validation of NeuroXM.

neuroxm-overview.png